Efficacy and Safety of Ceftazidime/Avibactam in Monotherapy or Combination Therapy Against Carbapenem Resistant Enterobacteriaceae: A Meta-analysis

OBJECTIVE To evaluate the efficacy and safety of ceftazidime/avibactam(CAZ/AVI) in monotherapy or combination therapy against carbapenem resistant enterobacteriaceae(CRE) infection. METHODS CNKI, Wanfang Data, CBM, PubMed, The Cochrane Library, Web of Science and Embase were searched by computer from construction to April 2021. To investigate the study of CAZ/AVI monotherapy and combination therapy for CRE infection. After data extraction and quality assessment of the eligible studies, RevMan 5.3 statistical software was used for meta-analysis. RESULTS A total of 13 studies involving 1 452 patients were included. The results of meta-analysis showed that compared with the combined treatment of CAZ/AVI, the mortality rateRR=0.98, 95%CI(0.82, 1.17), P=0.82, microbial clearance rateRR=1.02, 95%CI(0.8, 1.28), P=0.89 and the clinical cure rateRR=0.97, 95%CI(0.83, 1.13), P=0.66 of monotherapy had no statistically significant. CONCLUSION Based on the current study results, there is no significant difference in the efficacy and safety of CAZ/AVI monotherapy and combination therapy for CRE, which needs to be verified by more prospective studies and randomized controlled studies.